The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Emiltatug ledadotin (Emi-Le): A B7-H4-directed dolasynthen antibody-drug conjugate (ADC) being investigated in phase 1 dose expansion in patients with triple negative breast cancer who received at least one prior topoisomarase-1 inhibitor ADC.
 
Hyo Han
Consulting or Advisory Role - Arvinas; Pfizer
Research Funding - Arvinas (Inst); Celcuity (Inst); Department of Defense (Inst); Eisai; Ellipses Pharma; Mersana; Pfizer (Inst); Phoenix Pharmaceuticals (Inst); Pionyr (Inst); QuantumLeap Health (Inst); Senhwa Biosciences (Inst); Zymeworks (Inst)
 
Kevin Kalinsky
Employment - EQRx (I)
Stock and Other Ownership Interests - EQRx (I)
Consulting or Advisory Role - AstraZeneca; bioTheranostics; Cullinan Oncology; Daiichi Sankyo/Astra Zeneca; eFFECTOR Therapeutics; Genentech/Roche; Gilead Sciences; Lilly; Menarini Silicon Biosystems; Merck; mersana; Mersana; Myovant Sciences; Novartis; Pfizer; Prelude Therapeutics; ProteinQure; Puma Biotechnology; RayzeBio; Regor; Relay Therapeutics; Takeda
Research Funding - Ascentage Pharma (Inst); AstraZeneca (Inst); Daichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Seagen (Inst)
 
Nour Abuhadra
No Relationships to Disclose
 
Antonio Giordano
Consulting or Advisory Role - Pfizer; Pfizer; Pfizer; Pfizer
Research Funding - Cardiff Oncology (Inst)
Travel, Accommodations, Expenses - Pfizer
 
David Starks
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Lilly; Faeth Therapeutics; Verastem
 
Gerburg Wulf
Stock and Other Ownership Interests - Selecta Biosciences (I)
Consulting or Advisory Role - Totus Medicines
Research Funding - Boundless Bio (Inst); Celgene (Inst); Gilead Sciences (Inst); Mersana (Inst); Pfizer (Inst); PureTech (Inst); PureTech (Inst); PureTech (Inst); PureTech (Inst); Seagen (Inst); Totus Medicines (Inst)
Patents, Royalties, Other Intellectual Property - Pin1 as a marker for abnormal cell growth Patent number: 8129131; Pin1 inhibitors (Inst)
 
Nicholas McAndrew
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; GoodRx; Novartis
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Dizal Pharma (Inst); Eisai (Inst); Loxo (Inst); Mersana (Inst); Novartis (Inst); Seattle Genetics/Astellas (Inst)
Travel, Accommodations, Expenses - Novartis
 
Joyce O'Shaughnessy
Honoraria - AADi; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Oncology; DualityBio; Eisai; Ellipses Pharma; Exact Sciences; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; HiberCell; Jazz Pharmaceuticals; Johnson & Johnson; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Sanofi; Seagen; Stemline Therapeutics; Summit Therapeutics; Tempus; Tersera
Consulting or Advisory Role - AADi; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Oncology; DualityBio; Eisai; Ellipses Pharma; Exact Sciences; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; HiberCell; Jazz Pharmaceuticals; Johnson & Johnson; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Sanofi; Seagen; Stemline Therapeutics; Summit Therapeutics; Tempus; Tersera
Travel, Accommodations, Expenses - Aptitude Health; Daiichi Sankyo; DAVA Oncology; Lilly; Merck; Novartis; Roche
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Nancy Chan
Honoraria - Daiichi Sankyo/Astra Zeneca; Novartis
Consulting or Advisory Role - Daiichi Sankyo
Research Funding - Merck
 
Kristen Kelley
Consulting or Advisory Role - Immunogen
Speakers' Bureau - Immunogen
Research Funding - Mersana
Travel, Accommodations, Expenses - Immunogen
 
Ritesh Parajuli
Honoraria - Gilead Sciences; Merck; Stemline Therapeutics
Consulting or Advisory Role - Stemline Therapeutics
Speakers' Bureau - Gilead Sciences; Merck
Travel, Accommodations, Expenses - Gilead Sciences; Merck
 
Amy Weise
Employment - N/A
Leadership - N/A
Stock and Other Ownership Interests - N/A
Honoraria - N/A
Consulting or Advisory Role - N/A
Speakers' Bureau - N/A
Research Funding - N/A
Patents, Royalties, Other Intellectual Property - N/A
Expert Testimony - N/A
Travel, Accommodations, Expenses - N/A
Other Relationship - N/A
 
Arvind Chaudhry
Stock and Other Ownership Interests - Immunomedics; Novartis
Research Funding - Abbvie; Arcus Biosciences; AstraZeneca; BeiGene; Gilead Sciences; Medlink; Merck; Mersana
 
Judy Wang
Consulting or Advisory Role - Fusion Pharmaceuticals
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Adagene (Inst); Agenus (Inst); Allorion Therapeutics (Inst); Alterome Therapeutics (Inst); Apollo (Inst); Artios (Inst); Astellas Pharma (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioNTech SE (Inst); Biostar (Inst); BioTheryX (Inst); Blueprint Medicines (Inst); BMS GmbH & Co. KG (Inst); Boehringer Ingelheim (Inst); C4 Therapeutics (Inst); Celgene/Bristol-Myers Squibb (Inst); Centessa Pharmaceuticals (Inst); Circle Pharma (Inst); Compass Therapeutics (Inst); Compugen (Inst); Conjupro Biotherapeutics (Inst); Cullinan Oncology (Inst); cyteir (Inst); D3 Bio (Inst); Daiichi Sankyo/UCB Japan (Inst); DualityBio (Inst); Edgewood Oncology (Inst); Ellipses Pharma (Inst); Erasca, Inc (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Genmab (Inst); Georgiamune (Inst); GlaxoSmithKline (Inst); Hotspot Therapeutics (Inst); IgM Biosciences (Inst); Immune-Onc Therapeutics (Inst); Immunitas (Inst); Immunogen (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Kineta (Inst); Klus Pharma (Inst); Kumquat (Inst); Kura Oncology (Inst); Kymab (Inst); Loxo/Lilly (Inst); LSK Global (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MBQ Pharma (Inst); Medikine (Inst); MediLink Therapeutics (Inst); Menarini (Inst); Merck KGaA (Inst); Mersana (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Nurix (Inst); Olema Oncology (Inst); OnCusp Therapeutics (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Pyxis (Inst); Qilu Puget Sound Biotherapeutics (Inst); Quanta Therapeutics (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Step Pharma (Inst); Syndax (Inst); Tango Therapeutics (Inst); TeneoBio (Inst); Treadwell Therapeutics (Inst); Vividion Therapeutics (Inst); Xencor (Inst); Zai Lab (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - NGM Biopharmaceuticals
 
Debra Richardson
Honoraria - Zentalis
Consulting or Advisory Role - Abbvie; AstraZeneca; Daiichi Sankyo/UCB Japan; Eisai; Genmab; GlaxoSmithKline; Immunogen; Incyclix Bio; Mersana; ProfoundBio; Repare Therapeutics
Research Funding - A2A Pharmaceuticals (Inst); aadi (Inst); Acrivon Therapeutics (Inst); Allorian (Inst); Aravive (Inst); Arch Oncology (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); CanariaBio (Inst); Celsion (Inst); Clovis Oncology (Inst); DualityBio (Inst); GlaxoSmithKline (Inst); Hookipa Biotech (Inst); Immunogen/Abbvie (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Nimbus Therapeutics (Inst); Nurix (Inst); OnCusp Therapeutics (Inst); Plexxikon (Inst); PMV Pharma (Inst); ProfoundBio (Inst); Scorpion Therapeutics (Inst); Shattuck Labs (Inst); Tubulis GmbH (Inst); Valerion Therapeutics, LLC (Inst)
Travel, Accommodations, Expenses - Genmab; Society of Gynecologic Oncology
 
Dario Roque
Honoraria - Intuitive Surgical
Consulting or Advisory Role - GlaxoSmithKline; Merck
Speakers' Bureau - GlaxoSmithKline; Merck
Research Funding - Bristol Myers Squibb Foundation; Gilead Sciences (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Intuitive Surgical; Merck
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Dava Oncology
Consulting or Advisory Role - AstraZeneca; Becton Dickinson; Calibr; Cybrexa Therapeutics; Daiichi Sankyo/Astra Zeneca; DAVA Pharmaceuticals; Debiopharm Group; EcoR1 Capital; eFFECTOR Therapeutics; Elevation Oncology; Exelixis; GT Aperion; Guardant Health; Harbinger Health; Incyte; Jazz Pharmaceuticals; LegoChem Biosciences; Loxo/Lilly; Menarini Group; Mersana; Molecular Templates; OnCusp Therapeutics; Protai; Ribometrix; Seagen; Tempus; Theratechnologies; Zentalis; Zymeworks
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); Guardant Health (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Cholangiocarcinoma Foundation; Dava Oncology; ESMO; European Organisation for Research and Treatment of Cancer (EORTC)
 
Caroline Rogalski
Employment - Mersana
Stock and Other Ownership Interests - Mersana
 
Erika Hamilton
Consulting or Advisory Role - Accutar Biotechnology (Inst); Arvinas (Inst); AstraZeneca (Inst); Circle Pharma (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Entos (Inst); Fosun Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Jefferies (Inst); Johnson and Johnson (Inst); Lilly (Inst); Medical Pharma Services (Inst); Mersana (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Stemline Therapeutics (Inst); Tempus (Inst); Theratechnologies (Inst); Tubulis GmbH (Inst); Verascity Science (Inst); Zentalis (Inst)
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Akeso Biopharma (Inst); Amgen (Inst); Aravive (Inst); ArQule (Inst); Artios (Inst); Arvinas (Inst); AstraZeneca (Inst); AtlasMedx (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Bliss Biopharmaceutical (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squib (Inst); Cascadian Therapeutics (Inst); Clovis Oncology (Inst); Compugen (Inst); Context Therapeutics (Inst); Cullinan Oncology (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Dantari (Inst); Deciphera (Inst); Duality Biologics (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Ellipses Pharma (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Inspirna (Inst); InventisBio (Inst); Jacobio (Inst); K-Group Beta (Inst); Karyopharm Therapeutics (Inst); Kind Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Myriad Genetics (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Oncothyreon (Inst); ORIC Pharmaceuticals (Inst); Orinove (Inst); Orum Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); ProfoundBio (Inst); Radius Health (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Repertoire Immune Medicines (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Stemline Therapeutics (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Tolmar (Inst); Torque (Inst); Treadwell Therapeutics (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)